Notably, previous work has implicated BIRC3: i) in GBM therapeutic resistance [36]; (ii) as a biomarker for the mesenchymal GBM habitat in patients [37]; (iii) as a mediator of hypoxia-driven survival adaptation through HIF1α [37]; and (iv) as a facilitator of stemness reprogramming in GBM [38]. Here, BIRC3 is linked to glioblastoma.